The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Phase I Study of Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic Irinotecan for Unresectable Hepatic Metastases From Colorectal Cancer
Abstract
PURPOSE: To determine the maximum-tolerated dose (MTD) and dose-limiting toxicities of concurrent systemic irinotecan and hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone in patients with unresectable hepatic metastases from colorectal cancer, to determine the safety of this combination in patients who have undergone cryosurgery, and to evaluate the pharmacokinetic effects of HAI FUDR on the metabolism of irinotecan. PATIENTS AND METHODS: Forty-six previously treated patients with unresectable liver metastases and no known extrahepatic disease were treated concurrently with intravenous irinotecan weekly for 3 weeks and with HAI of FUDR and dexamethasone for 14 days (both were recycled in 28 days). Parallel cohorts of patients treated with or without cryosurgery were entered at escalating dose levels. RESULTS: The MTD for patients who did not undergo cryosurgery was 100 mg/m 2 of irinotecan weekly for 3 weeks every 4 weeks with concurrent HAI FUDR (0.16 mg/kg/d × pump volume/flow rate) plus dexamethasone for 14 days of a 28-day cycle. The dose-limiting toxicities were diarrhea and neutropenia. The response rate (complete and partial) among all patients who did not undergo cryosurgery was 74%. All patients in the cryosurgery group responded, and seven of the eight cryosurgery patients developed normal positron emission tomography scans after chemotherapy. HAI FUDR had no effect on the metabolism of irinotecan. CONCLUSION: Combination therapy with HAI FUDR and dexamethasone plus systemic irinotecan may be safely administered to patients with unresectable hepatic metastases from colorectal cancer. The MTD has been reached for patients with unresectable disease, and we continue to investigate the MTD for patients who have undergone cryosurgery. Although the main objective of this study was to evaluate the toxicity of the combined regimen, a high response rate (74%) was observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Individual Comparisons by Ranking Methods
Wilcoxon, F. (1945) · Biometrics Bulletin · doi:10.2307/3001968 · Cited by 15,354
Meta-Analysis Group In Cancer (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.5.252 · Cited by 441
Cited by
Kemeny, N. E., Niedzwiecki, D., Hollis, D. R., Lenz, H.-J., Warren, R. S., Naughton, M. J., Weeks, J. C., Sigurdson, E. R., Herndon, J. E., Zhang, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8166 · Cited by 417
Self-citationClinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
Malet-Martino, M., & Martino, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-4-288 · Cited by 382
Leonard, G. D., Brenner, B., & Kemeny, N. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.349 · Cited by 314
Self-citationHeffernan, N., Cella, D., Webster, K., Odom, L., Martone, M., Passik, S., Bookbinder, M., Fong, Y., Jarnagin, W., & Blumgart, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.093 · Cited by 279
Self-citation
Metadata
- Authors
- Kemeny, N., Gonen, M., Sullivan, D., Schwartz, L., Benedetti, F., Saltz, L., Stockman, J., Fong, Y., Jarnagin, W., Bertino, J., Tong, W., & Paty, P.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-05-15
- Volume
- 19
- Issue
- 10
- Pages
- 2687-2695
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2269945922
- Cited by
- 184
- References
- 2
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic Irinotecan for Unresectable Hepatic Metastases From Colorectal Cancer. https://app.cochat.ai/papers/10.1200/jco.2001.19.10.2687
- The paper
- Kemeny, N., Gonen, M., Sullivan, D., Schwartz, L., Benedetti, F., Saltz, L., Stockman, J., Fong, Y., Jarnagin, W., Bertino, J., Tong, W., & Paty, P. (2001). Phase I Study of Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic Irinotecan for Unresectable Hepatic Metastases From Colorectal Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2001.19.10.2687
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.